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simulated errors had gamma values greater than 1, and fail 
the criteria. In addition to dwell positions and times analysis, 
the system was capable of determining the transit time 
between dwell positions and its effect on the estimated dose 
delivered when compared against the treatment plan. 
 
Figure 1 - The position-time gamma analysis of the modified 
plan. 
Conclusions: Our application of the developed quality 
assurance system 'magic phantom', to HDR brachytherapy has 
demonstrated ability to perform the verification of all HDR 
treatment plans. This device has shown potential to be the 
comprehensive QA solution for the entire treatment delivery, 
with further development of this system focused on real time 
in vivo source tracking.  
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Purpose/Objective: One of the important proceedings of 
brachytherapy during the last years was the clinical 
implementation of modern planning algorithms. To provide 
guidelines to the medical physicist the AAPM TG-186 
published a report that describes procedures for 
commissioning new treatment planning algorithms (TPSs) in 
brachytherapy. To evaluate the guidance of this report from 
the end-users perspective we describe in this work the 
commissioning process of a commercial model-based dose 
calculation algorithm (MBDCA) for an HDR afterloading device 
in our clinic according to TG-186. We furthermore study 
complemental dose measurements. 
Materials and Methods:The TPS BrachyVision v11.0.47 
utilizing the dose calculation algorithm Acuros v1.5.0 for an 
Ir-192 HDR GammaMedplus afterloader (Varian Medical 
System, Palo Alto, CA) was used for this study. In the first 
step the commissioning process, as recommended by the TG-
186 report, was followed for level 1. Dose comparisons 
between TG-43 formalism and Acuros were carried out in 
water medium for a single source scenario of 40700 U. 
Moreover hand calculations were performed for several 
points of interest using along away table for the relevant TG-
43 consensus data. 
Measurements in a water tank (40x40x40 cm3) using a 
Semiflex chamber, type 31010, (PTW Freiburg, Germany) 
were conducted. Dose measurements are in particular of 
interest to validate the impact of heterogeneities in the 
Acuros module. They were carried out at various points of 
interest, laterally and distally positioned from the source. 
Therefor the source was either positioned in an implant 
needle made of steel or in a shielded 90° vaginal cylinder of 
3.5 cm diameter. This shielded cylinder is also virtually 
available for dose calculation as template in the applicator 
library of the BrachyVision/Acuros system. 
Results: Results of computations and measurements in water 
are summarized in Table 1. Hand and TG-43 based 
calculations are close to results of the Acuros computations 
(better than 2% for all points). As expected, dose 
measurements close to the source show deviations (about 
30% at 1,14 cm), but reached reasonable accuracy at longer 
distances (e.g. 5% at 7,11 cm). 
Dose values behind the shielding of the vaginal applicator are 
shown in Figure 1. Good agreement was reached between 
measurements and the results of the MBDCA. TG-43 
formalism takes heterogeneities not in to account, so the 
computed doses are not accurate behind the shielding. 
 
 
Conclusions: Commissioning of a MBDCA is well feasible when 
following the TG-186 report, level 1. In addition dose 
measurements in water can complete the procedure to check 
the impact of heterogeneities in the medium. 
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Purpose/Objective: Dose surface maps (DSM) provide spatial 
features of the rectal wall dose distribution which has been 
shown to correlate with tissue toxicity in different ways 
(Buettner et al 2009). This study aims to develop the 
methodology and assess feasibility of using DSM to 
accumulate rectal wall dose from both external beam 
radiotherapy (EBRT) and brachytherapy (BT) in cervical 
cancer patients. This was previously not possible using 
conventional dose volume histogram due to lack of spatial 
information and challenges with anatomical difference 
between the two therapeutic modalities. 
